Interaction reference
GLP-1 receptor agonists with Statins
No clinically meaningful interaction with GLP-1s. Statins remain standard of care in most patients on GLP-1 therapy.
Continue your statin as prescribed — no adjustment needed when starting a GLP-1.
Also known as: atorvastatin, rosuvastatin, simvastatin, Lipitor, Crestor
Per-GLP-1 breakdown
- Wegovysemaglutide 2.4 mgNo documented interaction
Mechanism: No pharmacokinetic interaction. Both classes reduce cardiovascular events through different mechanisms; concurrent use is the norm in high-risk patients.
What to do: Continue current statin dose. Statins are protective; GLP-1 cardiovascular benefit is additive, not redundant.
- ZepboundtirzepatideNo documented interaction
Mechanism: No pharmacokinetic interaction. Both classes reduce cardiovascular events through different mechanisms; concurrent use is the norm in high-risk patients.
What to do: Continue current statin dose. Statins are protective; GLP-1 cardiovascular benefit is additive, not redundant.
- OzempicsemaglutideNo documented interaction
Mechanism: No pharmacokinetic interaction. Both classes reduce cardiovascular events through different mechanisms; concurrent use is the norm in high-risk patients.
What to do: Continue current statin dose. Statins are protective; GLP-1 cardiovascular benefit is additive, not redundant.
- MounjarotirzepatideNo documented interaction
Mechanism: No pharmacokinetic interaction. Both classes reduce cardiovascular events through different mechanisms; concurrent use is the norm in high-risk patients.
What to do: Continue current statin dose. Statins are protective; GLP-1 cardiovascular benefit is additive, not redundant.
- FoundayoorforglipronNo documented interaction
Mechanism: No pharmacokinetic interaction. Both classes reduce cardiovascular events through different mechanisms; concurrent use is the norm in high-risk patients.
What to do: Continue current statin dose. Statins are protective; GLP-1 cardiovascular benefit is additive, not redundant.
Sources
- GLP-1 cardiovascular outcomes — concurrent statin use (opens in a new tab) — NEJM (SUSTAIN, LEADER trials)